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Abstract
Background: Pancreatic beta-cells proliferate following administration of the beta-cell toxin streptozotocin. Defining the
conditions that promote beta-cell proliferation could benefit patients with diabetes. We have investigated the effect of
insulin treatment on pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice, and, in addition, report on a
new approach to quantify beta-cell regeneration in vivo.
Methodology/Principal Findings: Streptozotocin-induced diabetic were treated with either syngeneic islets transplanted
under the kidney capsule or subcutaneous insulin implants. After either 60 or 120 days of insulin treatment, the islet
transplant or insulin implant were removed and blood glucose levels monitored for 30 days. The results showed that both
islet transplants and insulin implants restored normoglycemia in the 60 and 120 day treated animals. However, only the 120-
day islet and insulin implant groups maintained euglycemia (,200 mg/dl) following discontinuation of insulin treatment.
The beta-cell was significantly increased in all the 120 day insulin-treated groups (insulin implant, 0.6960.23 mg; and islet
transplant, 0.9160.23 mg) compared non-diabetic control mice (1.5460.25 mg). We also show that we can use
bioluminescent imaging to monitor beta-cell regeneration in living MIP-luc transgenic mice.
Conclusions/Significance: The results show that insulin treatment can promote beta-cell regeneration. Moreover, the
extent of restoration of beta-cell function and mass depend on the length of treatment period and overall level of glycemic
control with better control being associated with improved recovery. Finally, real-time bioluminescent imaging can be used
to monitor beta-cell recovery in living MIP-luc transgenic mice.
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Introduction
Insulin-secreting pancreatic beta-cells proliferate in response to
increasing demand for insulin and also after physiological injury
[1,2,3,4,5,6,7,8]. It is generally accepted that beta-cells have a
finite life span and that dying beta-cells are continuously replaced
[3,9,10,11,12]. This notion raises the possibility of enhancing base-
line replication of beta-cells as a therapeutic approach for the
treatment of diabetes patients with type 1 or type 2 diabetes.
Indeed, there are clinical case-reports of beta-cell regeneration
enabling the complete recovery from type 1 diabetes [13].
However, in the majority of patients, the reported level of
recovery is not sufficient to cure, or even maintain glucose
homeostasis [7,8]. A better understanding of the physiological
conditions and molecular mechanisms regulating beta-cell prolif-
eration and/or regeneration are necessary in order for beta-cell
replication-based therapies to become a reality.
We recently described functional beta-cell regeneration in a
mouse model of streptozotocin (STZ)-induced diabetes [14]. Here,
we extend these observations by investigating the effects of insulin
treatment and glycemic control on beta-cell regeneration in this
model. Current methods for quantifying beta-cell regeneration
require the sacrifice of mice and analysis of pancreatic sections,
thus precluding the real-time measurement of beta-cell regener-
ation. As a consequence, the kinetics of beta-cell regeneration are
poorly understood. We report a new approach that allows studies
of beta-cell regeneration in living mice utilizing bioluminescent
imaging and MIP-luc transgenic mice [15].
Materials and Methods
Mice
C57BL/6 mice obtained NCI (Frederick, MD) or Jackson
Laboratory (Bar Harbor, ME) were used as donors and recipients
of kidney subcapsular islet transplants. CD1 transgenic mice
expressing firefly (Photinus pyralis) luciferase (luc) under the control
of the mouse insulin I promoter (MIP- luc) [15] were used as
recipients of kidney subcapsular islet transplantation. 9–12 week
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injection of STZ (150 mg/kg, Sigma Chemical, St. Louis, MO).
Diabetic mice with non-fasted blood glucose values .400 mg/dl
for more than 2 consecutive days (SureStep; Lifescan, Milpitas,
CA) were used as recipients of islet grafts or insulin implants. All
studies were performed in accordance to protocols approved by
the University of Chicago Institutional Animal Care and Use
Committee.
Islet Isolation and Transplantation
Syngeneic islets from C57BL/6 mice were isolated following
intraductal collagenase digestion (Collagenase P, 0.3 mg/ml;
Roche, Indianapolis, IN) and purification by Ficoll gradient
centrifugation (Sigma, St. Louis, MO) as previously described
[14,16]. Approximately 200 islets were transplanted under the
kidney capsule.
Exogneous Insulin Implants
Insulin was administered via subcutaneous ‘LinBit Implants for
Mice’ (LinShin, Toronto, ON, Canada). The implants were
titrated for blood glucose levels of ,250 mg/dl.
Blood Glucose Monitoring
Random non-fasted blood glucose levels were determined three
times weekly from the tail vein using a SureStep glucometer.
Bioluminescent Imaging
Bioluminescent optical imaging was performed using a Xeno-
gen IVIS 200 imaging system (Xenogen, Alameda, CA) as
previously described [15]. Briefly, MIP-luc mice were fasted for
4 h, shaved, then anesthetized with isofluorane (using the
Xenogen system). Mice were placed on their sides on the imaging
stage and an overlay image was initially taken. Mice were then
injected IP with 15 mg/ml D-luciferin in sterile PBS (150 mg/kg)
and exactly 14 min after injection of D-luciferin, a bioluminescent
image was captured utilizing an exposure time of 1 minute.
Subsequent image processing including quantification of biolumi-
nescence was conducted using Living Image Software v. 2.05
(Xenogen).
Histological Studies
Beta-mass was determined as described previously [14]. Briefly,
the pancreas was removed, weighed, fixed, embedded and then
serially step-sectioned. Every 10th section was stained with anti-
insulin polyclonal antibody (Zymed, South San Francisco, CA;
,10 sections per mouse) and images of each section were captured
on a Zeiss Axiovert 200 M microscope. The insulin positive and
total pancreas area were quantified with Image J (National
Institutes of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/),
and the relative ratio of insulin positive areas to the entire pancreas
area was determined. The beta-cell mass was calculated by
multiplying the relative ratio by the total weight of the pancreas.
Intraperitoneal Glucose Tolerance Test
An intraperitoneal glucose tolerance test (IPGTT) was per-
formed as previously described [14]. Briefly, after four hours of
fasting, the mice received an intraperitoneal injection of dextrose
(2 g/kg), and blood glucose levels determined from the tail vein at
30-minute intervals.
Statistics
Data are presented as means6SEM and evaluated for statistical
significance by ANOVA (SuperANOVA v. 1.11; Abacus Con-
cepts, Berkeley, CA). A P value of ,0.05 was considered to be
significant.
Results
Effect of Insulin Treatment on Beta-Cell Function in STZ-
Diabetic Mice
The experimental design to study beta-cell regeneration was
divided into two phases: treatment and monitoring.
Treatment Phase. STZ-induced C57BL/6 diabetic female
mice, with non-fasted blood glucose values .400 mg/dl for more
than 2 consecutive days, were randomly assigned to the islet
transplant or insulin implant group. Mice (N=10 per group) were
then monitored for either 60 or 120 days with three times weekly
blood glucose measurements.
Monitoring Phase. After either 60 or 120 days, the islet
transplant was removed by nephrectomy and the insulin implant
removed. Blood glucose monitoring was continued for an
additional 30 days to allow for the assessment of endogenous
beta-cell function. At the end of this 30 day monitoring phase (i.e.
90 or 150 days after induction of diabetes with STZ), the mice
were sacrificed and histology performed to quantify beta-cell
mass.
Both islet transplantation and insulin treatment were
effective at preventing hypergylcemia and recurrence of
diabetes (Table 1 and Fig. 1A), with blood glucose control by
islet transplantation superior to insulin implants (139.467.5
and 181.668.3 mg/dl respectively, P,0.05). Following the
removal of the transplanted islets or discontinuation of insulin
therapy, all treatment groups showed a significant (P,0.05)
increase in blood glucose levels. Both the 60-day islet transplant
and implant groups redeveloped diabetic glucose levels during
the Monitoring Phase (255.3625. and 280.9635.8 mg/dl,
respectively). In contrast, the 120-day islet transplant and
insulin implant groups maintained stable non-diabetic blood
glucose levels (188.6631.7 and 194.2627.3 mg/dl, respective-
ly). At the end of the 30-day monitoring phase, mice from both
120-day groups underwent an IPGTT (Fig. 1B). Both groups
showed an abnormal glucose profile compared to non-diabetic
controls.
Effect of Insulin Treatment on Beta-Cell Mass in STZ-
Diabetic Mice
There was no significant increase in beta-cell mass in the 60-
day-insulin-treated groups compared to STZ-treated controls
(untreated STZ-control group, 0.0960.01 mg; islet transplant,
0.1460.09 mg; and insulin implant, 0.1860.13 mg) (Table 2). In
contrast, there was a significant increase in beta-cell mass in both
the 120-day-insulin-treated groups compared to untreated STZ-
induced diabetic mice (islet transplant, 0.9160.23 mg; insulin
implant, 0.6960.22 mg). The maximum beta-cell regeneration
occurred in the 120-day islet transplant group achieving a 60%
recovery of beta-cell mass that was statistically greater than the
45% recovery in 120-day insulin implant group (P,0.05). The
islets from the 120-day islet transplant group were large and
densely populated with insulin-producing beta-cells as compared
to the other treatment groups (Fig. 2).
Real-Time Quantification of Beta-Cell Recovery
Traditional measures of beta-cell mass preclude real-time
quantification and thus the kinetics of beta-cell regeneration
cannot be accurately ascertained. Our data suggest that significant
beta-cell regeneration occurred in the 60–120 day post-STZ
treatment period, but we were not able to define the kinetics of
Beta-Cell Regeneration in Mice
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whether biweekly bioluminescence imaging could successfully be
used to quantify beta-cell mass following destruction and
regeneration. Because bioluminescence emission is a dynamical
chemical reaction dependent on luciferin availability, numerous
optimization experiments were initially performed to determine
the time point (14 minutes post luciferin injection) at which
maximal bioluminescence emission could be captured. All
bioluminescence measurements were then performed in precisely
the same manner to allow for results at different time points to be
compared.
STZ-induced diabetic MIP-luc female mice (C57BL/6 back-
ground) were treated with 200 syngeneic wild-type C57BL/6 islets
placed under the kidney capsule. The transplanted islets do not
express the MIP-luc transgene, and consequently, the biolumines-
cent signal reflects the endogenous beta-cell mass. The transplant-
ed islets were removed at 120 days via nephrectomy beta-cell
function monitored for an additional 30 days. The baseline
bioluminescent signal was similar for all five MIP-luc mice.
After STZ-induced diabetes, bioluminescence decreased con-
tinued to do so, reaching a nadir approximately 60 days after
the induction of diabetes in all five mice (Fig. 3). After 60 days
post-STZ treatment phase, four of the five mice (M1, M3, M9
and M12) showed a persistent increase in bioluminescent
signal. In contrast, M2 demonstrated a transient increase in
bioluminescent that eventually was lost. At 120 days post-STZ
treatment, the bioluminescent signal of M1, M3, M9, and M12
showed a 5.261.5 fold increase compared to their nadir while
M2, did not.
All five MIP- luc mice maintained normal random blood glucose
levels (148.3626 mg/dl) prior to nephrectomy, indicating appro-
priate function of the transplanted islets. However, following
nephrectomy, M1, M3, M9 and M12 were able to maintain
glycemic control (180647, 136630, 166620, and 152637 mg/
Figure 1. Glycemic Control in Streptozotocin-induced Diabetic Mice. A. Non-fasted (random) blood glucose throughout the treatment and
monitoring phases. B. IPGTT comparing glucose tolerance in 120-day insulin-treated STZ-diabetic mice and non-diabetic controls. Txp – transplant.
doi:10.1371/journal.pone.0008749.g001
Table 1. Blood glucose levels (mg/dl) in STZ-diabetic mice treated with insulin by insulin implant or islet transplant under the
kidney capsule.
60-day insulin implant 60-day islet transplant 120-day insulin implant 120-day islet transplant
Treatment Phase 183.3618.8 141.4626.3 171.8622.7 143.4618.7
Monitoring Phase 280.9635.8 255.3625.2 194.2627.3 188.6631.7
doi:10.1371/journal.pone.0008749.t001
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beta-cells. In contrast, M2, demonstrated severe hyperglycemia
(500 mg/dl) following nephrectomy, consistent with the lack of
recovery of bioluminescent signal at 120-day post-STZ treatment
(Figure 3C; 0.28% of pre-STZ levels). Of note is that although M1,
M3, M9 and M12 maintained normal glycemic control following
nephrectomy, the animals with the largest bioluminescent signal at
120 days post-STZ treatment (M3, M9 and M12) maintained the
tightest glycemic control while mouse M1, which had the lowest
signal, had the poorest glycemic control. Thus, relatively small
differences in bioluminescence between individual mice appear to
be associated with dramatic differences in glycemic control,
highlighting the sensitivity of this experimental approach to
monitor beta-cell mass regeneration in vivo.
Discussion
Recent reports of functional pancreatic beta-cell regeneration in
murine models [17,18] has generated much excitement and
controversy [3,19]. Despite the increasingly accepted notion that
pancreatic beta-cells have the ability to regenerate, either from
remaining beta-cells or existing beta-cell precursors, and to restore
euglycemia after the induction of diabetes in laboratory rodent
models, the understanding and clinical relevance of beta-cell
regeneration is still incomplete. In particular, observations that
beta-cell regeneration derives primarily from existing beta-cells
and that insulin secreting beta-cells remain functional in patients
with established type 1 diabetes, raise the possibility that beta-cell
regeneration may contribute to the recovery in patients with
autoimmune diabetes [20,21,22,23]. The results of the studies
described here suggest that insulin treatment by implants or islet
transplantation promotes beta-cell regeneration in the STZ-
diabetic mouse model of beta-cell regeneration, and does so in a
time dependent manner with longer treatment periods associated
with greater recovery. They also suggest that the overall degree
control of glycemic control affects regeneration with better control
accelerating recovery of beta-cell mass and function. Further
studies are needed to determine the optimal length of time of
insulin treatment for complete recovery of beta-cell mass and
function in this model.
Studies of beta-cell regeneration in the MIP-luc transgenic
mouse model may provide additional insight into the process of
beta-cell regeneration by facilitating sequential real-time measure-
ments of beta-cell mass in living animals [15,24,25,26]. Following
STZ-treatment bioluminescence continued decline to a nadir at
day 60, followed by a spontaneous increase in endogenous beta-
cell bioluminescence from day 60–120 post-STZ. Notably small
differences in recovery of bioluminescence (0.28–2.13% of pre-
STZ bioluminescence levels) were associated with dramatic
differences in the control of blood glucose. Also the restoration
of beta cell mass measured by bioluminescence at day 0–120 post-
STZ was quantitatively lower than that determined by conven-
tional morphometric analysis, which was performed at 90 or 150
days post-STZ treatment. The different times at which beta-cell
mass was determined and the differential sensitivity of these
techniques under low beta-cell mass conditions could have
contributed to these differences. More extensive measurements
of beta cell mass under the two conditions are necessary to clarify
the bases for these differences in perceived regeneration as
determined by the two experimental approaches. Despite these
differences, only the bioluminescence approach can permit the
quantification of changes in beta-cell mass in an individual mouse
over time, which we believe can provide valuable insights into the
kinetics of beta-cell regeneration that the more conventional
approach cannot.
In conclusion, our studies of beta-cell regeneration in the STZ-
diabetic mouse may have implications for patients with type 1
Table 2. Beta-cell mass (mg) in STZ-diabetic mice treated with insulin by insulin implant or islet transplant under the kidney
capsule.
Non-diabetic
control
Untreated STZ-
diabetic mice
60-day insulin
implant
60-day islet
transplant
120-day insulin
implant
120-day islet
transplant
Beta-cell mass (mg) 1.5260.25 0.0960.01 0.1860.13 0.1460.09 0.6960.22* 0.9160.23*
Untreated STZ-diabetic B6 mice were examined 4–8 days after STZ-induced diabetes, which when untreated results in severe diabetes and death.
*P,0.05 compared to untreated STZ-diabetic mice.
doi:10.1371/journal.pone.0008749.t002
Figure 2. Representative pancreatic islets showing insulin
staining (brown) in untreated STZ-diabetic mice, non-diabetic
control and STZ-diabetic mice treated with insulin implants or
islet transplant (txp) under the kidney capsule for 60 or 120
days (40x).
doi:10.1371/journal.pone.0008749.g002
Beta-Cell Regeneration in Mice
PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8749diabetes and suggest that if the ongoing immunological destruction
of beta-cells can be prevented, proliferation of the remaining beta-
cells in the presence of insulin (and possibly other agents) may lead
to a restoration of normal glucose tolerance.
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